Last reviewed · How we verify
Sentagliptin Phosphate - single dose
Sentagliptin Phosphate - single dose is a DPP-4 inhibitor Small molecule drug developed by Second Affiliated Hospital of Soochow University. It is currently in Phase 3 development for Type 2 diabetes.
Sentagliptin phosphate is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones to enhance glucose-dependent insulin secretion.
Sentagliptin Phosphate is a small molecule with unknown mechanism of action, as its specific action is not described in the provided information. It has been studied in clinical trials as a single dose intervention for conditions including Ischemic Stroke and Diabetes Mellitus.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sentagliptin Phosphate - single dose |
|---|---|
| Sponsor | Second Affiliated Hospital of Soochow University |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
DPP-4 inhibitors like sentagliptin phosphate work by blocking the enzyme DPP-4, which breaks down incretin hormones. This leads to increased levels of incretin hormones, which in turn stimulate the release of insulin from the pancreas in a glucose-dependent manner.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sentagliptin Phosphate - single dose CI brief — competitive landscape report
- Sentagliptin Phosphate - single dose updates RSS · CI watch RSS
- Second Affiliated Hospital of Soochow University portfolio CI
Frequently asked questions about Sentagliptin Phosphate - single dose
What is Sentagliptin Phosphate - single dose?
How does Sentagliptin Phosphate - single dose work?
What is Sentagliptin Phosphate - single dose used for?
Who makes Sentagliptin Phosphate - single dose?
What drug class is Sentagliptin Phosphate - single dose in?
What development phase is Sentagliptin Phosphate - single dose in?
What are the side effects of Sentagliptin Phosphate - single dose?
What does Sentagliptin Phosphate - single dose target?
Related
- Drug class: All DPP-4 inhibitor drugs
- Target: All drugs targeting DPP-4
- Manufacturer: Second Affiliated Hospital of Soochow University — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing